CO6260076A2 - Derivados de uracilo o timina para el tratamiento de la hepatitis c - Google Patents
Derivados de uracilo o timina para el tratamiento de la hepatitis cInfo
- Publication number
- CO6260076A2 CO6260076A2 CO10030957A CO10030957A CO6260076A2 CO 6260076 A2 CO6260076 A2 CO 6260076A2 CO 10030957 A CO10030957 A CO 10030957A CO 10030957 A CO10030957 A CO 10030957A CO 6260076 A2 CO6260076 A2 CO 6260076A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- salts
- compounds
- compositions
- carbon
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 150000003839 salts Chemical class 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- -1 hydroxy, methyl Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97287707P | 2007-09-17 | 2007-09-17 | |
| US9679108P | 2008-09-13 | 2008-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260076A2 true CO6260076A2 (es) | 2011-03-22 |
Family
ID=39948002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10030957A CO6260076A2 (es) | 2007-09-17 | 2010-03-16 | Derivados de uracilo o timina para el tratamiento de la hepatitis c |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8415351B2 (enExample) |
| EP (2) | EP2222646B1 (enExample) |
| JP (2) | JP5734654B2 (enExample) |
| KR (2) | KR101660360B1 (enExample) |
| CN (2) | CN102746239B (enExample) |
| AR (2) | AR070027A1 (enExample) |
| AU (1) | AU2008302448B2 (enExample) |
| BR (1) | BRPI0816994B8 (enExample) |
| CA (2) | CA2976793A1 (enExample) |
| CL (2) | CL2008002794A1 (enExample) |
| CO (1) | CO6260076A2 (enExample) |
| CR (2) | CR11316A (enExample) |
| DO (2) | DOP2010000084A (enExample) |
| ES (1) | ES2453591T3 (enExample) |
| GT (1) | GT201000061A (enExample) |
| IL (1) | IL204547A (enExample) |
| IN (1) | IN2012DN05113A (enExample) |
| MX (2) | MX2010002905A (enExample) |
| MY (1) | MY162760A (enExample) |
| NZ (3) | NZ618277A (enExample) |
| PA (1) | PA8796201A1 (enExample) |
| PE (2) | PE20130209A1 (enExample) |
| PH (1) | PH12013500365A1 (enExample) |
| RU (2) | RU2543620C2 (enExample) |
| SG (1) | SG183733A1 (enExample) |
| TW (2) | TWI534137B (enExample) |
| UA (1) | UA117800C2 (enExample) |
| UY (1) | UY31344A1 (enExample) |
| WO (1) | WO2009039127A1 (enExample) |
| ZA (2) | ZA201204223B (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104628654A (zh) | 2007-09-17 | 2015-05-20 | 艾伯维巴哈马有限公司 | 抗感染嘧啶及其用途 |
| CN105693626A (zh) | 2007-09-17 | 2016-06-22 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN102746239B (zh) * | 2007-09-17 | 2016-02-10 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| MX2010005356A (es) * | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| EP2334662A1 (en) | 2008-09-26 | 2011-06-22 | F. Hoffmann-La Roche AG | Pyrine or pyrazine derivatives for treating hcv |
| RU2524573C2 (ru) * | 2009-03-24 | 2014-07-27 | Эбботт Лэборетриз | Способ получения (e)-n-(3-трет-бутил-5-(2,4-диоксо-3,4-дигидропиримидин-1(2н)-ил)-2-метокси-стирил)фенил)метансульфонамида и промежуточные соединения для его получения |
| RU2552533C2 (ru) * | 2009-03-25 | 2015-06-10 | Эббви Инк. | Противовирусные соединения и их применения |
| JP2012522013A (ja) * | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| EP2421831A1 (en) | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| AR077004A1 (es) | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
| SG176976A1 (en) * | 2009-06-24 | 2012-02-28 | Hoffmann La Roche | Heterocyclic antiviral compound |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| BR112012005616A2 (pt) | 2009-09-21 | 2016-06-21 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| BR112012012085A2 (pt) * | 2009-11-21 | 2016-05-17 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| BR112012014299A2 (pt) * | 2009-12-14 | 2016-07-05 | Hoffmann La Roche | composto de antivírus heterocíclicos |
| US9216952B2 (en) * | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| BR112013000245A2 (pt) | 2010-07-07 | 2016-05-24 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| EP3461556A1 (en) | 2010-07-16 | 2019-04-03 | AbbVie Ireland Unlimited Company | Phosphine ligands for catalytic reactions |
| EP3056486B1 (en) * | 2010-07-16 | 2018-07-11 | AbbVie Ireland Unlimited Company | Process for preparing intermediates for antiviral compounds |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| CN103068819B (zh) | 2010-08-13 | 2014-08-13 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| TWI558400B (zh) | 2011-03-18 | 2016-11-21 | 艾伯維有限公司 | 苯基尿嘧啶化合物之調配物 |
| SG10201602384VA (en) * | 2011-03-31 | 2016-05-30 | Konstanze Schäfer | Perfluorinated compounds for the non-viral transfer of nucleic acids |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | １，３−ジヨードヒダントイン類の製造方法 |
| US9040516B2 (en) | 2011-08-01 | 2015-05-26 | Sumitomo Dainippon Pharma Co., Ltd. | Uracil derivative and use thereof for medical purposes |
| EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| SE1450130A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| CN104334529B (zh) | 2012-05-15 | 2017-03-15 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物 |
| JP6078639B2 (ja) | 2012-05-15 | 2017-02-08 | ノバルティス アーゲー | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 |
| EA201492005A1 (ru) | 2012-05-15 | 2015-04-30 | Новартис Аг | Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1 |
| US9340537B2 (en) | 2012-05-15 | 2016-05-17 | Novatis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| JP2015522022A (ja) | 2012-06-27 | 2015-08-03 | アッヴィ・インコーポレイテッド | Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置 |
| EP2887941B1 (en) | 2012-08-21 | 2018-07-11 | AbbVie Ireland Unlimited Company | Process for preparing antiviral compounds |
| JP6266635B2 (ja) * | 2012-10-18 | 2018-01-24 | アッヴィ・インコーポレイテッド | ピリミジンジオン誘導体化合物の製剤 |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| WO2015002952A1 (en) | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for treating hcv |
| BR112016000241B1 (pt) | 2013-07-08 | 2021-06-22 | Bayer Cropscience Aktiengesellschaft | Compostos pesticidas derivados de sulfeto de arila e sulfóxido de arila, formulação, seus usos, método para controle de pragas e método de proteção de semente ou planta |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| EP3099295A1 (en) | 2014-01-28 | 2016-12-07 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
| SI3102576T1 (sl) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals, Llc | Inhibitorji dihidropirolopiridina ROR-gama |
| WO2015197028A1 (en) * | 2014-06-28 | 2015-12-30 | Sunshine Lake Pharma Co., Ltd. | Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| MY187540A (en) | 2014-08-01 | 2021-09-28 | Nuevolution As | Compounds active towards bromodomains |
| WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
| BR112017007460A2 (pt) | 2014-10-14 | 2017-12-19 | Vitae Pharmaceuticals Inc | inibidores de di-hidropirrolopiridina de ror-gama |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
| WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
| WO2017019828A1 (en) * | 2015-07-30 | 2017-02-02 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| WO2017087608A1 (en) | 2015-11-20 | 2017-05-26 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| KR20200053481A (ko) | 2017-07-24 | 2020-05-18 | 비타이 파마슈티컬즈, 엘엘씨 | RORγ의 억제제 |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| EP3774804A1 (en) | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| JP7785663B2 (ja) * | 2019-09-16 | 2025-12-15 | ノバルティス アーゲー | 二機能性分解誘導薬及びそれらの使用方法 |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| ATE169915T1 (de) | 1990-02-15 | 1998-09-15 | Takeda Chemical Industries Ltd | Pyrimidindionderivate, deren herstellung und verwendung |
| NL9001075A (enExample) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| PL207160B1 (pl) | 1999-12-06 | 2010-11-30 | Hoffmann La Roche | Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| IL167954A (en) * | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | History of pyrimidine |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR100589964B1 (ko) * | 2003-06-13 | 2006-06-19 | 주식회사 엘지생명과학 | Ｃ형 간염 바이러스의 억제제 |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| AR061570A1 (es) * | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| CN104628654A (zh) | 2007-09-17 | 2015-05-20 | 艾伯维巴哈马有限公司 | 抗感染嘧啶及其用途 |
| CN105693626A (zh) * | 2007-09-17 | 2016-06-22 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN102746239B (zh) * | 2007-09-17 | 2016-02-10 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
-
2008
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh not_active IP Right Cessation
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
| AR056964A1 (es) | Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos | |
| ES2601518T3 (es) | Composiciones plaguicidas | |
| AR039665A1 (es) | Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa | |
| AR055635A1 (es) | Uso de sulfonanilidas como herbicidas | |
| AR082562A1 (es) | Derivados de isoxazolina como agentes antiparasitarios | |
| DK2203430T3 (da) | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) | |
| AR050540A1 (es) | Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide | |
| CO6210770A2 (es) | Compuestos 2-aril-5-heterociclil-ciclohexan-1, 3 diona y su uso como herbicidas | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| ECSP088149A (es) | 3-acilaminobenzanilidas insecticidas | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| AR062109A1 (es) | Derivados sustituidos de espirocetal y uso de los mismos como farmacos terapeuticos para la diabetes. composiciones farmaceuticas. | |
| AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
| MX2007003636A (es) | Composiciones funguicidas. | |
| AR056882A1 (es) | Derivados del fungicida n- cicloalquil- bencil- amida | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| UY30387A1 (es) | Nuevos compuestos | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR046959A1 (es) | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio | |
| MX337320B (es) | Análogos halogenados de agentes anti-fibroticos. | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR074353A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica. | |
| ECSP088257A (es) | Derivados de amida | |
| CO6331307A2 (es) | Derivados de imidazo[1,2alfa]piridin-2-carboxamidas su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |